We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A long-term, multicenter, open-label study of risperidone in elderly patients with psychosis.
- Authors
Davidson, M.; Harvey, P. D.; Vervarcke, J.; Gagiano, C. A.; De Hooge, J. D.; Bray, G.; Dose, M.; Barak, Y.; Haushofer, M.
- Abstract
<ABSHEAD>Rationale</ABSHEAD>Studies have shown that risperidone is safe and efficacious in young and middle-aged adults with chronic schizophrenia, but considerably fewer data are availabale on the treatment of elderly patients with schizophrenia or other psychotic disorders, particularly long-term outcomes. <ABSHEAD>Objective</ABSHEAD>A 12-month, open-label study was conducted to assess the effects of risperidone in elderly, chronically ill, psychotic patients. <ABSHEAD>Methods</ABSHEAD>This study enrolled 180 elderly, chronically ill, psychotic patients (median age, 72 years [range 54–89]), 97 of whom completed the 12-month study. At endpoint, the mean dose of risperidone was 3.7 mg/day. <ABSHEAD>Results</ABSHEAD>Clinical improvement (≥20% reduction in Positive and Negative Syndrome Score [PANSS] total score) was achieved by 54% of patients at endpoint. There were significant reductions in PANSS total, subscale (positive, negative, and general psychopathology), and cognition cluster scores at endpoint (p <0.001). Clinical Global Impressions severity of illness scores showed continued improvement through month 12 (p <0.001). In contrast, PANSS data from a historical comparable control group of patients receiving conventional antipsychotic agents showed no symptom improvement over a 12-month treatment period. The severity of preexisting extrapyramidal symptoms (EPS) in patients treated with risperidone decreased significantly from baseline to endpoint (p <0.001), and the use of antiparkinsonian medication decreased from 41.1% of patients before the trial to 25.6% during the trial. There were no spontaneous reports of tardive dyskinesia (TD) and the incidence of assessed TD was 4.3% in contrast to the expected 26% reported in middle-aged and elderly patients receiving conventional antipsychotic agents for 1 year. <ABSHEAD>Conclusions</ABSHEAD>Long-term treatment with risperidone was associated with continued symptom improvement, a decrease in the severity of preexising EPS, and a low incidence of TD in elderly psychotic patients. Copyright © 2000 John Wiley & Sons, Ltd.
- Subjects
RISPERIDONE; PSYCHOSES; OLDER people; SCHIZOPHRENIA; GERIATRIC psychiatry; DRUG efficacy
- Publication
International Journal of Geriatric Psychiatry, 2000, Vol 15, Issue 6, p506
- ISSN
0885-6230
- Publication type
Article
- DOI
10.1002/1099-1166(200006)15:6<506::AID-GPS146>3.0.CO;2-V